Table 1.
Characteristics of training and validation cohorts.
| Variables | Training cohort (n = 259) | Validation cohort (n = 274) | ||||
|---|---|---|---|---|---|---|
|
SIRI > 1.36 (n = 122) |
SIRI ≤ 1.36 (n = 137) |
P-value |
SIRI > 1.36 (n = 117) |
SIRI ≤ 1.36 (n = 157) |
P-value | |
| Age (>65 vs. ≤65 years) | 85/37 | 79/58 | 0.045* | 69/48 | 91/66 | 0.866 |
| Gender (Male vs. Female) | 92/30 | 93/44 | 0.181 | 96/21 | 88/69 | <0.001* |
| ASA grade (≥3 vs. <3) | 34/88 | 27/110 | 0.122 | 19/98 | 27/130 | 0.834 |
| BMI (≥25 vs. <25, Kg/m2) | 14/108 | 37/100 | 0.002* | 33/84 | 59/98 | 0.104 |
| Hydronephrosis (Yes vs. No) | 84/38 | 88/49 | 0.432 | 81/36 | 107/50 | 0.849 |
| Surgical approach (laparoscopic vs. open) | 36/86 | 53/84 | 0.121 | 102/15 | 145/12 | 0.155 |
| NLR, Mean ± SD | 4.93 ± 0.33 | 2.05 ± 0.06 | <0.001* | 4.74 ± 0.26 | 2.12 ± 0.09 | <0.001* |
| PLR, Mean ± SD | 195.65 ± 10.19 | 116.45 ± 3.56 | <0.001* | 162.69 ± 6.70 | 121.32 ± 4.53 | <0.001* |
| MLR, Mean ± SD | 0.52 ± 0.03 | 0.24 ± 0.08 | <0.001* | 0.48 ± 0.02 | 0.23 ± 0.01 | <0.001* |
| Anemia (Yes vs. No) | 67/55 | 41/96 | <0.001* | 38/79 | 42/115 | 0.302 |
| Hypoproteinemia (Yes vs. No) | 17/105 | 5/132 | 0.003* | 14/103 | 10/147 | 0.105 |
| CKD stage | 0.008* | 0.006* | ||||
| CKD 1 | 7 | 21 | 35 | 29 | ||
| CKD 2 | 36 | 52 | 45 | 46 | ||
| CKD 3 | 61 | 55 | 31 | 73 | ||
| CKD 4 | 13 | 8 | 6 | 9 | ||
| CKD 5 | 5 | 1 | 0 | 0 | ||
| Tumor size (≥4 vs. <4cm) | 30/92 | 23/114 | 0.120 | 34/83 | 22/135 | 0.002* |
| Tumor site | 0.342 | 0.337 | ||||
| Pelvicalyceal | 80 | 85 | 64 | 85 | ||
| Ureter | 35 | 48 | 43 | 65 | ||
| Both | 7 | 4 | 10 | 7 | ||
| Multifocality (Yes vs. No) | 30/92 | 20/117 | 0.042* | 29/88 | 37/120 | 0.815 |
| Pathologic T stage | <0.001* | 0.002* | ||||
| pT1 | 29 | 51 | 32 | 60 | ||
| pT2 | 34 | 54 | 22 | 46 | ||
| pT3 | 38 | 24 | 49 | 45 | ||
| pT4 | 21 | 8 | 14 | 6 | ||
| N stage (N1 vs. N0) | 18/104 | 6/131 | 0.004* | 12/105 | 5/152 | 0.016* |
| Tumor grade (≥3 vs. <3) | 94/28 | 106/31 | 0.951 | 92/25 | 105/52 | 0.032* |
| LVI (Yes vs. No) | 28/94 | 13/124 | 0.003* | 23/94 | 15/142 | 0.017* |
| Adjuvant therapy (Yes vs. No) | 17/105 | 11/126 | 0.127 | 35/82 | 39/118 | 0.349 |
| Follow-up duration, months, median (IQR) | 27.50 (11.48–47.63) | 39.70 (20.05–69.65) | <0.001* | 32.90 (17.95–54.30) | 52.00 (34.95–73.50) | <0.001* |
| All–cause death, n (%) | 61 (50.00%) | 32 (23.36%) | <0.001* | 56 (47.86%) | 29 (18.47%) | <0.001* |
| Cancer-specific death, n (%) | 48 (39.34%) | 25 (18.25%) | <0.001* | 46 (39.32%) | 20 (12.74%) | <0.001* |
| Metastasis, n (%) | 59 (48.36%) | 42 (30.66%) | <0.001* | 53 (45.3%) | 37 (23.57%) | <0.001* |
*
Statistically significant.